Is VXF a Good ETF to Buy?
Vanguard’s Extended Market ETF (VXF) is a broad fund made…
Buy
68
HIMS Quote, Financials, Valuation and Earnings
Last price:
$34.38
Seasonality move
:
3.58%
Day range:
$37.42 - $41.32
52-week range:
$11.20 - $72.98
Dividend yield:
0%
P/E ratio:
75.72x
P/S ratio:
6.56x
P/B ratio:
19.06x
Volume:
21.1M
Avg. volume:
27.3M
1-year change:
187.15%
Market cap:
$9.1B
Revenue:
$1.5B
EPS (TTM):
$0.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HIMS
Hims & Hers Health
|
$470.5M | $0.22 | 92.32% | 312.9% | $43.43 |
|
EWCZ
European Wax Center
|
$52.2M | $0.06 | -8.05% | 13.44% | $8.06 |
|
GROV
Grove Collaborative Holdings
|
$48.8M | -$0.15 | -18.49% | -44.44% | $2.50 |
|
KVUE
Kenvue
|
$3.8B | $0.26 | -5.39% | 54.63% | $23.80 |
|
SKIN
The Beauty Health
|
$78M | -$0.09 | -19.69% | -12.5% | $1.72 |
|
WALD
Waldencast PLC
|
$70.4M | -$0.07 | -- | -- | $5.76 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HIMS
Hims & Hers Health
|
$40.89 | $43.43 | $9.1B | 75.72x | $0.00 | 0% | 6.56x |
|
EWCZ
European Wax Center
|
$5.88 | $8.06 | $263.2M | 25.61x | $0.00 | 0% | 1.27x |
|
GROV
Grove Collaborative Holdings
|
$1.64 | $2.50 | $64.5M | -- | $0.00 | 0% | 0.28x |
|
KVUE
Kenvue
|
$23.04 | $23.80 | $44B | 43.47x | $0.21 | 3.54% | 2.87x |
|
SKIN
The Beauty Health
|
$1.29 | $1.72 | $160.1M | -- | $0.00 | 0% | 0.50x |
|
WALD
Waldencast PLC
|
$3.47 | $5.76 | $426.3M | -- | $0.00 | 0% | 1.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HIMS
Hims & Hers Health
|
-- | 7.338 | -- | 1.38x |
|
EWCZ
European Wax Center
|
84.51% | -1.418 | 106.6% | 2.00x |
|
GROV
Grove Collaborative Holdings
|
54.96% | 1.822 | 41.26% | 1.28x |
|
KVUE
Kenvue
|
46.77% | 1.501 | 20.79% | 0.65x |
|
SKIN
The Beauty Health
|
90.23% | 0.014 | 308.53% | 5.35x |
|
WALD
Waldencast PLC
|
21.71% | -0.007 | 29.49% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HIMS
Hims & Hers Health
|
$369.5M | $18.6M | 32.03% | 32.03% | 3.87% | $59.5M |
|
EWCZ
European Wax Center
|
$40.4M | $9.5M | 2.28% | 9.59% | 16.58% | $14.8M |
|
GROV
Grove Collaborative Holdings
|
$25.6M | -$6.7M | -29.08% | -125.41% | 3.35% | $264K |
|
KVUE
Kenvue
|
$2.1B | $557M | 5.43% | 9.84% | 13.49% | $661M |
|
SKIN
The Beauty Health
|
$40.6M | -$21.5M | -3.93% | -41.24% | -17.61% | $8.2M |
|
WALD
Waldencast PLC
|
-- | -- | -7.46% | -9.22% | -- | -- |
Hims & Hers Health vs. Competitors
-
Which has Higher Returns HIMS or EWCZ?
European Wax Center has a net margin of 5.41% compared to Hims & Hers Health's net margin of 2.67%. Hims & Hers Health's return on equity of 32.03% beat European Wax Center's return on equity of 9.59%.
Company Gross Margin Earnings Per Share Invested Capital HIMSHims & Hers Health76.81% $0.11 $476.7M EWCZEuropean Wax Center72.93% $0.03 $474.8M -
What do Analysts Say About HIMS or EWCZ?
Hims & Hers Health has a consensus price target of $43.43, signalling upside risk potential of 6.21%. On the other hand European Wax Center has an analysts' consensus of $8.06 which suggests that it could grow by 37.12%. Given that European Wax Center has higher upside potential than Hims & Hers Health, analysts believe European Wax Center is more attractive than Hims & Hers Health.
Company Buy Ratings Hold Ratings Sell Ratings HIMSHims & Hers Health4 8 1 EWCZEuropean Wax Center3 5 1 -
Is HIMS or EWCZ More Risky?
Hims & Hers Health has a beta of 1.368, which suggesting that the stock is 36.817% more volatile than S&P 500. In comparison European Wax Center has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HIMS or EWCZ?
Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. European Wax Center offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. European Wax Center pays out 31.9% of its earnings as a dividend. European Wax Center's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HIMS or EWCZ?
Hims & Hers Health quarterly revenues are $481.1M, which are larger than European Wax Center quarterly revenues of $55.4M. Hims & Hers Health's net income of $26M is higher than European Wax Center's net income of $1.5M. Notably, Hims & Hers Health's price-to-earnings ratio is 75.72x while European Wax Center's PE ratio is 25.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 6.56x versus 1.27x for European Wax Center. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HIMSHims & Hers Health6.56x 75.72x $481.1M $26M EWCZEuropean Wax Center1.27x 25.61x $55.4M $1.5M
-
Which has Higher Returns HIMS or GROV?
Grove Collaborative Holdings has a net margin of 5.41% compared to Hims & Hers Health's net margin of -2.77%. Hims & Hers Health's return on equity of 32.03% beat Grove Collaborative Holdings's return on equity of -125.41%.
Company Gross Margin Earnings Per Share Invested Capital HIMSHims & Hers Health76.81% $0.11 $476.7M GROVGrove Collaborative Holdings53.03% -$0.04 $58.5M -
What do Analysts Say About HIMS or GROV?
Hims & Hers Health has a consensus price target of $43.43, signalling upside risk potential of 6.21%. On the other hand Grove Collaborative Holdings has an analysts' consensus of $2.50 which suggests that it could grow by 52.44%. Given that Grove Collaborative Holdings has higher upside potential than Hims & Hers Health, analysts believe Grove Collaborative Holdings is more attractive than Hims & Hers Health.
Company Buy Ratings Hold Ratings Sell Ratings HIMSHims & Hers Health4 8 1 GROVGrove Collaborative Holdings2 0 0 -
Is HIMS or GROV More Risky?
Hims & Hers Health has a beta of 1.368, which suggesting that the stock is 36.817% more volatile than S&P 500. In comparison Grove Collaborative Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HIMS or GROV?
Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grove Collaborative Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. Grove Collaborative Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HIMS or GROV?
Hims & Hers Health quarterly revenues are $481.1M, which are larger than Grove Collaborative Holdings quarterly revenues of $48.3M. Hims & Hers Health's net income of $26M is higher than Grove Collaborative Holdings's net income of -$1.3M. Notably, Hims & Hers Health's price-to-earnings ratio is 75.72x while Grove Collaborative Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 6.56x versus 0.28x for Grove Collaborative Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HIMSHims & Hers Health6.56x 75.72x $481.1M $26M GROVGrove Collaborative Holdings0.28x -- $48.3M -$1.3M
-
Which has Higher Returns HIMS or KVUE?
Kenvue has a net margin of 5.41% compared to Hims & Hers Health's net margin of 8%. Hims & Hers Health's return on equity of 32.03% beat Kenvue's return on equity of 9.84%.
Company Gross Margin Earnings Per Share Invested Capital HIMSHims & Hers Health76.81% $0.11 $476.7M KVUEKenvue56.53% $0.15 $18.2B -
What do Analysts Say About HIMS or KVUE?
Hims & Hers Health has a consensus price target of $43.43, signalling upside risk potential of 6.21%. On the other hand Kenvue has an analysts' consensus of $23.80 which suggests that it could grow by 3.31%. Given that Hims & Hers Health has higher upside potential than Kenvue, analysts believe Hims & Hers Health is more attractive than Kenvue.
Company Buy Ratings Hold Ratings Sell Ratings HIMSHims & Hers Health4 8 1 KVUEKenvue3 12 0 -
Is HIMS or KVUE More Risky?
Hims & Hers Health has a beta of 1.368, which suggesting that the stock is 36.817% more volatile than S&P 500. In comparison Kenvue has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HIMS or KVUE?
Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kenvue offers a yield of 3.54% to investors and pays a quarterly dividend of $0.21 per share. Hims & Hers Health pays -- of its earnings as a dividend. Kenvue pays out 150.68% of its earnings as a dividend.
-
Which has Better Financial Ratios HIMS or KVUE?
Hims & Hers Health quarterly revenues are $481.1M, which are smaller than Kenvue quarterly revenues of $3.7B. Hims & Hers Health's net income of $26M is lower than Kenvue's net income of $293M. Notably, Hims & Hers Health's price-to-earnings ratio is 75.72x while Kenvue's PE ratio is 43.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 6.56x versus 2.87x for Kenvue. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HIMSHims & Hers Health6.56x 75.72x $481.1M $26M KVUEKenvue2.87x 43.47x $3.7B $293M
-
Which has Higher Returns HIMS or SKIN?
The Beauty Health has a net margin of 5.41% compared to Hims & Hers Health's net margin of -23.21%. Hims & Hers Health's return on equity of 32.03% beat The Beauty Health's return on equity of -41.24%.
Company Gross Margin Earnings Per Share Invested Capital HIMSHims & Hers Health76.81% $0.11 $476.7M SKINThe Beauty Health51.58% -$0.15 $611.1M -
What do Analysts Say About HIMS or SKIN?
Hims & Hers Health has a consensus price target of $43.43, signalling upside risk potential of 6.21%. On the other hand The Beauty Health has an analysts' consensus of $1.72 which suggests that it could grow by 33.08%. Given that The Beauty Health has higher upside potential than Hims & Hers Health, analysts believe The Beauty Health is more attractive than Hims & Hers Health.
Company Buy Ratings Hold Ratings Sell Ratings HIMSHims & Hers Health4 8 1 SKINThe Beauty Health0 7 0 -
Is HIMS or SKIN More Risky?
Hims & Hers Health has a beta of 1.368, which suggesting that the stock is 36.817% more volatile than S&P 500. In comparison The Beauty Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HIMS or SKIN?
Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Beauty Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. The Beauty Health pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HIMS or SKIN?
Hims & Hers Health quarterly revenues are $481.1M, which are larger than The Beauty Health quarterly revenues of $78.8M. Hims & Hers Health's net income of $26M is higher than The Beauty Health's net income of -$18.3M. Notably, Hims & Hers Health's price-to-earnings ratio is 75.72x while The Beauty Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 6.56x versus 0.50x for The Beauty Health. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HIMSHims & Hers Health6.56x 75.72x $481.1M $26M SKINThe Beauty Health0.50x -- $78.8M -$18.3M
-
Which has Higher Returns HIMS or WALD?
Waldencast PLC has a net margin of 5.41% compared to Hims & Hers Health's net margin of --. Hims & Hers Health's return on equity of 32.03% beat Waldencast PLC's return on equity of -9.22%.
Company Gross Margin Earnings Per Share Invested Capital HIMSHims & Hers Health76.81% $0.11 $476.7M WALDWaldencast PLC-- -- $932M -
What do Analysts Say About HIMS or WALD?
Hims & Hers Health has a consensus price target of $43.43, signalling upside risk potential of 6.21%. On the other hand Waldencast PLC has an analysts' consensus of $5.76 which suggests that it could grow by 65.99%. Given that Waldencast PLC has higher upside potential than Hims & Hers Health, analysts believe Waldencast PLC is more attractive than Hims & Hers Health.
Company Buy Ratings Hold Ratings Sell Ratings HIMSHims & Hers Health4 8 1 WALDWaldencast PLC4 2 0 -
Is HIMS or WALD More Risky?
Hims & Hers Health has a beta of 1.368, which suggesting that the stock is 36.817% more volatile than S&P 500. In comparison Waldencast PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HIMS or WALD?
Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Waldencast PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. Waldencast PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HIMS or WALD?
Hims & Hers Health quarterly revenues are $481.1M, which are larger than Waldencast PLC quarterly revenues of --. Hims & Hers Health's net income of $26M is higher than Waldencast PLC's net income of --. Notably, Hims & Hers Health's price-to-earnings ratio is 75.72x while Waldencast PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 6.56x versus 1.46x for Waldencast PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HIMSHims & Hers Health6.56x 75.72x $481.1M $26M WALDWaldencast PLC1.46x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is PM Stock Up So Much?
Shares of cigarette giant Philip Morris (NYSE:PM) have advanced considerably…
Is Nvidia Stock Still Too Expensive or a Smart Buy?
The $2.8 trillion chip juggernaut NVIDIA Corporation (NASDAQ:NVDA) announced Q4…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3T
P/E Ratio: 34x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
53
SITM alert for Mar 6
SiTime [SITM] is down 2.22% over the past day.
Buy
71
ASTS alert for Mar 6
AST SpaceMobile [ASTS] is down 4.73% over the past day.
Sell
20
MRNA alert for Mar 6
Moderna [MRNA] is down 2.56% over the past day.
